NIMG-01. PREDICTING POST-STEREOTACTIC RADIOTHERAPY MAGNETIC RESONANCE IMAGE OUTCOMES OF BREAST CANCER METASTASES TO THE BRAIN
نویسندگان
چکیده
Abstract BACKGROUND Stereotactic radiosurgery (SRS) is a cornerstone in the management of Breast Cancer Metastases to Brain (BCMB). While control rates are high following SRS, radiation necrosis rare but potentially devastating long-term toxicity. There clinical need for automated/semi-automated methods assess tumor response and optimize RT plans local with minimal Multiparametric MRI (mpMRI), particularly Apparent Diffusion Coefficient water (ADC) maps, contain information that mechanistically relatable voxel-level RT. We report deep learning-based approach predict post-SRS ADC FLAIR, T2-weighted (T2W), T1-weighted unenhanced (T1W) contrast-enhanced (T1WCE) images, from pre-SRS T1W, T1WCE, T2W FLAIR delivered dose map. These “forward models” will enable oncologist simulate radiologic outcomes iteratively METHODS trained variant pix2pix Generative Adversarial Network (GAN) on map data 18 BCMB patients treated stereotactic confirmed controlled locally recurrent metastases. Patients were 1-40 Gy between 2013-2019. RESULTS On test 6 patients, forward model predicted values within Gross Tumor Volume (GTV) broadly agreement ground truth maps. In expectations, also predicts increasing post-RT GTV simulated doses range 1-71 Gy. have explored an inverse required produce “prescribed” GTV. CONCLUSIONS envision models assist initial plan optimization, while may be useful daily optimization.
منابع مشابه
Stereotactic radiotherapy in epithelial ovarian cancer brain metastases patients
BACKGROUND In this report we present the results of the retrospective (survival and classification) analyses of possible prognostic factors prolonging survival in epithelial ovarian cancer brain metastases patients after stereotactic radiotherapy. We focus on a wide range of available predictors to establish survival in patients with a good health status and no more than three lesions. METHOD...
متن کامل[Stereotactic radiosurgery and radiotherapy for brain metastases].
Brain metastases management is still controversial even though many trials are trying to define the respective roles of neurosurgery, whole-brain radiotherapy, single-dose stereotactic radiotherapy and fractionated stereotactic radiotherapy. In this article, we review data from trials that examine the role of radiosurgery and fractionated stereotactic radiotherapy in the management of brain met...
متن کاملHypofractionated stereotactic radiotherapy for the treatment of brain metastases.
BACKGROUND This retrospective review evaluated the efficacy and toxicity profiles of various dose fractionations using hypofractionated stereotactic radiotherapy (HSRT) in the treatment of brain metastases. METHODS Between 2004 and 2007, 36 patients with 66 brain metastases were treated with HSRT. Nine of these subjects were excluded because of the absence of post-treatment magnetic resonance...
متن کاملStereotactic Radiotherapy for Liver Metastases
Liver metastases are common in oncologic patients, causing substantial morbidity and mortality. Systemic therapy is now standard palliative treatment for most patients with liver metastases, often providing transient responses and increased overall survival. In selected oligometastatic patients, local treatment can lead to long disease-free intervals and even permanent disease control. Although...
متن کاملHypofractionated stereotactic radiotherapy for brain metastases larger than three centimeters
BACKGROUND To evaluate the efficacy and outcomes of hypofractionated stereotactic radiotherapy (HSRT) for brain metastases > 3 cm. METHODS From March 2003 to October 2009, 40 patients with brain metastases larger than 3 cm were treated by HSRT. HSRT was applied in 29 patients for primary treatment and in 11 patients for rescue. Single brain metastasis was detected in 21 patients. Whole brain ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neuro-oncology
سال: 2022
ISSN: ['1523-5866', '1522-8517']
DOI: https://doi.org/10.1093/neuonc/noac209.621